02/08/2022 Laigo Bio
Oncode Institute and ArgoBio launch Laigo Bio, a targeted protein degradation biotech with programs in oncology and neurological disorders
A collaboration for the creation of a company specialized in the development of a new biological approach for the treatment of cancer and neurological disorders. Argobio and the Oncode Institute will support the company's development to Series A financing. Utrecht (Netherlands), and Paris (France), February 08th 2022 - ArgoBio and Oncode Institute have...
16/12/2021 Kevad Bio
Argobio and GeneCode Partner on Parkinson’s Disease in Argobio’s First Announced Research Agreement
A collaboration to develop a new class of small molecule for the treatment of Parkinson's disease and other indications. Argobio will fund the development of this innovative project up to €3 million and incorporate a new specialized biotechnology company. With €50M in capital, Argobio and its team of experienced entrepreneurs-in-residence...
Argobio announces its launch with 50 M€ to create and develop pioneering biotech spinouts with the support of Bpifrance, Kurma Partners, Angelini Pharma, Evotec, and the Institut Pasteur
Argobio is a French start-up studio aiming at creating at least five ambitious therapeutic biotech spinouts over the next five years Argobio has 50 M€ of share capital committed by a syndicate of complementary and strategic investors with a shared goal to develop some of Europe’s most promising biotech innovations Argobio will incubate early-stage,...